司库奇尤单抗治疗期间的皮肤血管炎
Cutaneous Vasculitis During Secukinumab Treatment.
作者信息
da Silva Cendon Duran Camila, Barreto Santiago Mittermayer
机构信息
Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
出版信息
Eur J Case Rep Intern Med. 2020 Jul 28;7(10):001815. doi: 10.12890/2020_001815. eCollection 2020.
UNLABELLED
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab.
LEARNING POINTS
Treatment with biologics can cause vasculitis.The vasculitis may be independent of class of the biologic.Only five cases of vasculitis induced by secukinumab have been reported.
未标注
司库奇尤单抗是白细胞介素IL-17A的抑制剂，主要用于治疗银屑病、银屑病关节炎和强直性脊柱炎。尽管这种情况很少见，但该药物可能会引发反常反应，如皮肤血管炎。在全球范围内，之前仅报告过4例由司库奇尤单抗诱发的血管炎病例。我们在此报告巴西首例因司库奇尤单抗导致皮肤血管炎的病例，该患者患有外周型脊柱关节炎，在停用该药物并开始使用依那西普后病情得到明显缓解。临床医生应意识到司库奇尤单抗这种罕见但可能严重的不良反应。
学习要点
生物制剂治疗可导致血管炎。血管炎可能与生物制剂的类别无关。仅报告过5例由司库奇尤单抗诱发的血管炎病例。
Zotero 插件